AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

U.S. Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,562.00-8.00 (-0.18%)
At close: 5:07PM GMT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4,570.00
Bid4,540.00 x 6100
Ask4,630.00 x 13000
Day's Range4,558.50 - 4,665.60
52 Week Range3,680.00 - 5,505.00
Avg. Volume3,029,784
Market Cap57.72B
PE Ratio (TTM)16.53
Earnings DateN/A
Dividend & Yield2.80 (4.97%)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals6 hours ago

    $250M deal: AstraZeneca sells rights to cancer therapy

    AstraZeneca entered into an agreement to sell the rights to a cancer drug in the United States and Canada to TerSera Therapeutics for an upfront payment of $250. The deal could also net AstraZeneca up to $70 million in sales-related income if revenue milestones are met, along with recurring quarterly sales-based payments that are set at a mid-teen percent of product sales. TerSera Therapeutics, which has offices in Iowa and Illinois, acquired the rights to Zoladex, an injectable drug used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.

  • AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink
    Investor's Business Daily4 days ago

    AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink

    Pfizer and Tesaro could follow AstraZeneca which, early Friday, unveiled strong results from a trial of Lynparza in breast cancer.

  • TheStreet.com4 days ago

    Clovis, Tesaro Soar on Astrazeneca Phase Three News

    AstraZeneca shares, meanwhile, were less-than-moved by the news.